Mapi Pharma

Privately held: no public share price · Israel

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
Dopamine D3/D2 receptor (partial agonist)Small molecule
Schizophrenia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Cariprazine long-acting injection (Mapi Pharma)Phase 1/2Schizophrenia, Bipolar I Disorder, Major Depressive Disorder
Est. primary completion 2026-12-31 · NCT07185815 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 August 2026Topline resultCariprazine long-acting injection (Mapi Pharma)Cariprazine Depot Phase I/IIa Cohort 1 top-line results

Financial reports

No financial reports recorded.